60 search results for: Pathophysiology

ADVENT at ERS-ISIAN 2025
On Demand
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Dermatology
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Podcast

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

View more
Exploring the Potential Role of Biomarkers in Managing Bullous Pemphigoid
Dermatology
Exploring the Potential Role of Biomarkers in Managing Bullous Pemphigoid
expert video

Dr. Donna Culton discusses biomarkers in bullous pemphigoid and considers their potential clinical use.

View more
KOL Video Interview – Dr Amy Paller
Dermatology
KOL Video Interview – Dr Amy Paller
expert video

In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.

View more
The Clinical Presentation of CSU is Heterogeneous
Dermatology
The Clinical Presentation of CSU is Heterogeneous
expert video

Dr Hawkes provides an overview of the distinctive characteristics of wheals and angioedema in clinical manifestation

View more
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch
Dermatology
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch
expert video

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD

View more
IL-4 Contributes to Systemic Type 2 Inflammation in AD
Dermatology
IL-4 Contributes to Systemic Type 2 Inflammation in AD
expert video

In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.

View more
Type 2 Inflammation Within Skin Tissue in AD
Dermatology
Type 2 Inflammation Within Skin Tissue in AD
expert video

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.

View more
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation
Pulmonology
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation
interactivity

Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

View more
Heterogeneous Presentation and Diagnosis in Bullous Pemphigoid
Dermatology
Heterogeneous Presentation and Diagnosis in Bullous Pemphigoid
expert video

Dr. Donna Culton describes the heterogeneous presentation and diagnosis of bullous pemphigoid at EADV 2025

View more
KOL Video Interview – Dr Paula Luna
Dermatology
KOL Video Interview – Dr Paula Luna
expert video

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

View more
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis
Dermatology
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis
expert video

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.

View more